178 related articles for article (PubMed ID: 28410228)
21. Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia.
Wang Q; Qiu H; Jiang H; Wu L; Dong S; Pan J; Wang W; Ping N; Xia J; Sun A; Wu D; Xue Y; Drexler HG; Macleod RA; Chen S
Haematologica; 2011 Dec; 96(12):1808-14. PubMed ID: 21880637
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.
Loh ML; Zhang J; Harvey RC; Roberts K; Payne-Turner D; Kang H; Wu G; Chen X; Becksfort J; Edmonson M; Buetow KH; Carroll WL; Chen IM; Wood B; Borowitz MJ; Devidas M; Gerhard DS; Bowman P; Larsen E; Winick N; Raetz E; Smith M; Downing JR; Willman CL; Mullighan CG; Hunger SP
Blood; 2013 Jan; 121(3):485-8. PubMed ID: 23212523
[TBL] [Abstract][Full Text] [Related]
23. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
[TBL] [Abstract][Full Text] [Related]
24. JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines.
Porcu M; Gielen O; Cools J; De Keersmaecker K
Haematologica; 2009 Mar; 94(3):435-7. PubMed ID: 19176360
[No Abstract] [Full Text] [Related]
25. MicroRNA-520a-3p suppresses epithelial-mesenchymal transition, invasion, and migration of papillary thyroid carcinoma cells via the JAK1-mediated JAK/STAT signaling pathway.
Bi CL; Zhang YQ; Li B; Guo M; Fu YL
J Cell Physiol; 2019 Apr; 234(4):4054-4067. PubMed ID: 30206929
[TBL] [Abstract][Full Text] [Related]
26. A novel activating JAK1 mutation in chronic eosinophilic leukemia.
Shomali W; Damnernsawad A; Theparee T; Sampson D; Morrow Q; Yang F; Fernandez-Pol S; Press R; Zehnder J; Tyner JW; Gotlib J
Blood Adv; 2021 Sep; 5(18):3581-3586. PubMed ID: 34496019
[TBL] [Abstract][Full Text] [Related]
27. JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations.
Ren Y; Zhang Y; Liu RZ; Fenstermacher DA; Wright KL; Teer JK; Wu J
Sci Rep; 2013 Oct; 3():3042. PubMed ID: 24154688
[TBL] [Abstract][Full Text] [Related]
28. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia.
Xiang Z; Zhao Y; Mitaksov V; Fremont DH; Kasai Y; Molitoris A; Ries RE; Miner TL; McLellan MD; DiPersio JF; Link DC; Payton JE; Graubert TA; Watson M; Shannon W; Heath SE; Nagarajan R; Mardis ER; Wilson RK; Ley TJ; Tomasson MH
Blood; 2008 May; 111(9):4809-12. PubMed ID: 18160671
[TBL] [Abstract][Full Text] [Related]
29. Structural modeling of JAK1 mutations in T-cell acute lymphoblastic leukemia reveals a second contact site between pseudokinase and kinase domains.
Canté-Barrett K; Uitdehaag JC; Meijerink JP
Haematologica; 2016 May; 101(5):e189-91. PubMed ID: 26819051
[No Abstract] [Full Text] [Related]
30. The molecular genetic makeup of acute lymphoblastic leukemia.
Mullighan CG
Hematology Am Soc Hematol Educ Program; 2012; 2012():389-96. PubMed ID: 23233609
[TBL] [Abstract][Full Text] [Related]
31. Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains of JAK1.
Corbi FC; de Oliveira MB; Morelli VM; Han SW; Renauld JC; Knoops L; Colleoni GW
Leuk Lymphoma; 2014 May; 55(5):1176-80. PubMed ID: 23885837
[TBL] [Abstract][Full Text] [Related]
32. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
Song L; Rawal B; Nemeth JA; Haura EB
Mol Cancer Ther; 2011 Mar; 10(3):481-94. PubMed ID: 21216930
[TBL] [Abstract][Full Text] [Related]
33. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.
Porpaczy E; Tripolt S; Hoelbl-Kovacic A; Gisslinger B; Bago-Horvath Z; Casanova-Hevia E; Clappier E; Decker T; Fajmann S; Fux DA; Greiner G; Gueltekin S; Heller G; Herkner H; Hoermann G; Kiladjian JJ; Kolbe T; Kornauth C; Krauth MT; Kralovics R; Muellauer L; Mueller M; Prchal-Murphy M; Putz EM; Raffoux E; Schiefer AI; Schmetterer K; Schneckenleithner C; Simonitsch-Klupp I; Skrabs C; Sperr WR; Staber PB; Strobl B; Valent P; Jaeger U; Gisslinger H; Sexl V
Blood; 2018 Aug; 132(7):694-706. PubMed ID: 29907599
[TBL] [Abstract][Full Text] [Related]
34. Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia.
Tasian SK; Loh ML
Crit Rev Oncog; 2011; 16(1-2):13-24. PubMed ID: 22150304
[TBL] [Abstract][Full Text] [Related]
35. Philadelphia Chromosome-like Mixed-Phenotype Acute Leukemia Demonstrating P2RY8-CRLF2 Fusion and JAK1 Mutation.
Choi SM; Frederiksen JK; Ross CW; Bixby DL; Shao L
Am J Clin Pathol; 2017 Nov; 148(6):523-528. PubMed ID: 29140408
[TBL] [Abstract][Full Text] [Related]
36. N-Acetylcysteine Alters Disease Progression and Increases Janus Kinase Mutation Frequency in a Mouse Model of Precursor B-Cell Acute Lymphoblastic Leukemia.
Sams MP; Iansavitchous J; Astridge M; Rysan H; Xu LS; Rodrigues de Oliveira B; DeKoter RP
J Pharmacol Exp Ther; 2024 Mar; 389(1):40-50. PubMed ID: 38336380
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
Suryani S; Bracken LS; Harvey RC; Sia KC; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB
Mol Cancer Ther; 2015 Feb; 14(2):364-74. PubMed ID: 25504635
[TBL] [Abstract][Full Text] [Related]
38. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia.
Feng J; Li Y; Jia Y; Fang Q; Gong X; Dong X; Ru K; Li Q; Zhao X; Liu K; Wang M; Tian Z; Jia Y; Wang Y; Lin D; Wei H; Tang K; Mi Y; Wang J
J Hematol Oncol; 2017 Feb; 10(1):61. PubMed ID: 28245838
[TBL] [Abstract][Full Text] [Related]
39. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
[TBL] [Abstract][Full Text] [Related]
40. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
